Get 40% Off
😲 Missed the +20.8% surge in our stock strategy last month? Not again! Get premium insightsGet 40% Off Now

Cascadian Therapeutics Inc (CASC)

NASDAQ
Currency in USD
Disclaimer
10.02
0.00(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
9.9910.03
52 wk Range
0.0010.03
Prev. Close
10
Open
10
Day's Range
9.99-10.03
52 wk Range
0-0
Volume
0
Average Vol. (3m)
933,061
1-Year Change
0%
Shares Outstanding
55,317,212
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about CASC?
Vote to see community's results!
or

Cascadian Therapeutics Inc Company Profile

Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib clinical trials, one in combination with T-DM1 and another in combination with capecitabine and/or trastuzumab for the treatment of metastatic breast cancer. The company’s product pipeline also includes two preclinical-stage product candidates, which include CASC-578, a Chk1 cell cycle inhibitor; and CASC-674, an antibody against an immuno-oncology target. It has a license agreement with Array BioPharma Inc. to develop, manufacture, and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington. Cascadian Therapeutics, Inc. operates as a subsidiary of Seagen Inc.

Industry
-
Sector
-
Employees
71
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.